Default company panoramic image
Twitterlogo

Cellanyx Diagnostics

Harnessing predictive biomarkers enabled by microfluidics, Cellanyx predicts which "low-risk" patients are actually at risk of local and/or metastatic disease

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Boston, MA, USA
  • Currency USD
  • Founded January 2013
  • Employees 8
  • Incorporation Type LLC
  • Website cellanyx.com

Company Summary

Cellanyx Diagnostics is developing a proprietary living cell phenotypic cancer diagnostic platform to aid clinical decision making in cancer patients. The company’s unique ‘biopsy-on-a-chip’ provides quantitative and actionable, predictors of tumor aggressiveness, metastatic potential and adverse pathology based on multiple proprietary biomarkers from tumors. Cellanyx has demonstrated clinical proof-of-concept in prostate cancer.

Team

  • Default avatar
    Ashok Chander
    Chief Executive Officer, Founder

    SB, MIT; PhD, Columbia University

  • Default avatar
    Jonathan Varsanik
    VP Engineering

    SB, MIT; PhD, MIT

  • Default avatar
    Michael Manak
    VP Research & Development

    PhD, University of Florida; Post Doctoral Fellow, Harvard Medical School

  • 54b497fe a2cf 4b80 9473 486ff89004ed
    VP of Commercialization

    BS, UMN

  • 847a2935 4aba 4dad a140 d19c26f424ee
    Marketing Lead

    BS, University of California, San Diego; MS, Columbia University